Drug Combination Details
| General Information of the Combination (ID: C79218) | |||||
|---|---|---|---|---|---|
| Name | Cyclopamine NP Info | + | Erlotinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Brain cancer
[ICD-11: 2A00]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | POU5F1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | PROM1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Cells derived from glioblastoma patients | Glioblastoma | Homo sapiens | |||
| Experimental
Result(s) |
Synergic efficiency for erlotinib-cyclopamine association and provide a suitable in vitro model to explore drug combinations on GBM cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures. Neuro Oncol. 2012 Dec;14(12):1441-51. | |||
